🎉 M&A multiples are live!
Check it out!

LAVA Therapeutics Valuation Multiples

Discover revenue and EBITDA valuation multiples for LAVA Therapeutics and similar public comparables like Vivoryon Therapeutics, Pharming, and Galapagos.

LAVA Therapeutics Overview

About LAVA Therapeutics

LAVA Therapeutics NV is a biotechnology company. It is focused on transforming cancer treatment by developing a platform to selectively induce bispecific antibody utilizing the Gammabody platform for an undisclosed tumor associated antigen for the treatment of cancer.


Founded

2016

HQ

United States of America
Employees

34

Financials

LTM Revenue $8.5M

LTM EBITDA n/a

EV

-$40.8M

Valuation Multiples

Multiples.vc

Sign up to see

Valuation Multiples for 10K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

LAVA Therapeutics Financials

LAVA Therapeutics has a last 12-month revenue of $8.5M and a last 12-month EBITDA of n/a.

In the most recent fiscal year, LAVA Therapeutics achieved revenue of $12.0M and an EBITDA of -$23.5M.

LAVA Therapeutics expects next 12-month revenue of  XXX    and NTM EBITDA of  XXX

See LAVA Therapeutics valuation multiples based on analyst estimates

LAVA Therapeutics P&L

FY 2023 FY 2024 FY 2025 LTM NTM
Revenue $6.8M $12.0M XXX XXX XXX
Gross Profit n/a $3.3M XXX XXX XXX
Gross Margin NaN% 27% XXX XXX XXX
EBITDA -$40.2M -$23.5M XXX XXX XXX
EBITDA Margin -594% -196% XXX XXX XXX
Net Profit -$31.9M -$42.0M XXX XXX XXX
Net Margin -471% -350% XXX XXX XXX
Net Debt n/a n/a XXX XXX XXX

Financial data powered by Morningstar, Inc.

LAVA Therapeutics Stock Performance

As of April 15, 2025, LAVA Therapeutics's stock price is $1.

LAVA Therapeutics has current market cap of $30.5M, and EV of -$40.8M.

See LAVA Therapeutics trading valuation data

LAVA Therapeutics Stock Data

EV Market Cap Price 1D Price 1M Price 3M Price 12M EPS
-$40.8M $30.5M XXX XXX XXX XXX $-1.10

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Sign Up

LAVA Therapeutics Valuation Multiples

As of April 15, 2025, LAVA Therapeutics has market cap of $30.5M and EV of -$40.8M.

LAVA Therapeutics's trades at -4.8x LTM EV/Revenue multiple, and n/a LTM EBITDA.

Analysts estimate LAVA Therapeutics's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See valuation multiples for LAVA Therapeutics and 10K+ public comps

LAVA Therapeutics Financial Valuation Multiples

FY 2024 FY 2025E FY 2026E FY 2027E
EV -$40.8M XXX XXX XXX
EV/Revenue -3.4x XXX XXX XXX
EV/EBITDA 1.7x XXX XXX XXX
P/E -1.2x XXX XXX XXX
P/E/Growth n/a XXX XXX XXX
EV/FCF 2.1x XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get LAVA Therapeutics Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Sign Up

LAVA Therapeutics Valuation Multiples

LAVA Therapeutics's NTM/LTM revenue growth is -100%

LAVA Therapeutics's revenue per employee for the last fiscal year averaged $0.4M, while opex per employee averaged $1.2M for the same period.

Over next 12 months, LAVA Therapeutics's ratio of sales and marketing spend to revenue is estimated to be  XXX , while its R&D spend to revenue to be  XXX .

Analysts estimate LAVA Therapeutics's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See operational valuation multiples for LAVA Therapeutics and other 10K+ public comps

LAVA Therapeutics Operational Valuation Multiples

FY 2024 NTM FY 2025E FY 2026E FY 2027E
Revenue Growth 77% XXX XXX XXX XXX
EBITDA Margin -196% XXX XXX XXX XXX
EBITDA Growth -42% XXX XXX XXX XXX
Rule of 40 (SaaS-only) n/a XXX XXX XXX XXX
Revenue per Employee $0.4M XXX XXX XXX XXX
Opex per Employee $1.2M XXX XXX XXX XXX
S&M Expenses to Revenue n/a XXX XXX XXX XXX
G&A Expenses to Revenue 110% XXX XXX XXX XXX
R&D Expenses to Revenue 237% XXX XXX XXX XXX
Opex to Revenue 348% XXX XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics
Pharma Analytics
Private Equity
ERP Software
Developer Tools
Consumer SaaS
Streaming Platforms

LAVA Therapeutics Public Comps

See public comps and valuation multiples for Drug Development & Therapeutics comps
EV/Revenue EV/EBITDA
2025E 2026E 2027E 2025E 2026E 2027E
Julphar XXX XXX XXX XXX XXX XXX
Benevolent AI XXX XXX XXX XXX XXX XXX
Galapagos XXX XXX XXX XXX XXX XXX
Pharming XXX XXX XXX XXX XXX XXX
Vivoryon Therapeutics XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX

Valuation data powered by FactSet, Inc.

LAVA Therapeutics M&A and Investment Activity

LAVA Therapeutics acquired  XXX companies to date.

Last acquisition by LAVA Therapeutics was  XXXXXXXX, XXXXX XXXXX XXXXXX . LAVA Therapeutics acquired  XXXXXXXX for  XXX (EV/Revenue multiple of  XXX ).

See M&A valuation multiples

Latest Acquisitions by LAVA Therapeutics

Acquired Company EV EV/Revenue EV/EBITDA
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX

Get Verified M&A Valuation Multiples

Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.

Sign Up

About LAVA Therapeutics

When was LAVA Therapeutics founded? LAVA Therapeutics was founded in 2016.
Where is LAVA Therapeutics headquartered? LAVA Therapeutics is headquartered in United States of America.
How many employees does LAVA Therapeutics have? As of today, LAVA Therapeutics has 34 employees.
Who is the CEO of LAVA Therapeutics? LAVA Therapeutics's CEO is Mr. Stephen A. Hurly.
Is LAVA Therapeutics publicy listed? Yes, LAVA Therapeutics is a public company listed on NAS.
What is the stock symbol of LAVA Therapeutics? LAVA Therapeutics trades under LVTX ticker.
When did LAVA Therapeutics go public? LAVA Therapeutics went public in 2021.
Who are competitors of LAVA Therapeutics? Similar companies to LAVA Therapeutics include e.g. Julphar, Benevolent AI, Galapagos, Pharming.
What is the current market cap of LAVA Therapeutics? LAVA Therapeutics's current market cap is $30.5M
What is the current revenue of LAVA Therapeutics? LAVA Therapeutics's last 12-month revenue is $8.5M.
What is the current EV/Revenue multiple of LAVA Therapeutics? Current revenue multiple of LAVA Therapeutics is -4.8x.
What is the current revenue growth of LAVA Therapeutics? LAVA Therapeutics revenue growth between 2023 and 2024 was 77%.
Is LAVA Therapeutics profitable? Yes, LAVA Therapeutics is EBITDA-positive (as of the last 12 months).

Join Now Or Talk To Us

Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.